top of page
News & Events
Best poster award for Aseel at the 2024 MCS-ICS symposium!
Congrats to Aseel and Elias for presenting their work as posters at the 2024 MCS-ICS meeting! Special applause to Aseel for winning the Best Poster Prize!
NCK prize for outstanding young chemist
Congratulations to Raphael for receiving the 2024 NCK medicinal chemistry prize for outstanding young chemist, Medicinal Chemistry Section of the Israel Chemical Society (MCS-ICS).
New Review! - Small Molecules Targeting MicroRNAs
In this review, we explore advancements in drug discovery, focusing on the potential to selectively target specific disease-associated miRs.
Congratulation to Kisanet!
Congratulation to Kisanet!
We welcome Dipak and Omri!
Dipak is joining the lab as a Postdoc and Omri as a new M.Sc. student. Welcome and good luck!
New published article! Targeted Degradation of Structured RNAs via Ribonuclease-Targeting Chimeras (RiboTacs)
Check out our review and thoughts on the evolution of the RIBOTAC technology for degrading structured RNAs associated with diseases.
Congrats to Salma Haj yahya and Arijit Nandi!
Congrats to Salma Haj yahya and Arijit Nandi!
Congratulations to our Master's students, Salma Haj Yahya and Elias Khaskia.
Congratulations to two of our Master's students, Salma Haj Yahya and Elias Khaskia, for delivering amazing master seminar talks today!
You have made us proud!
You have made us proud!
New Research Article Published in Nature!
Target occupancy is often insufficient to elicit biological activity, particularly for RNA, compounded by the longstanding challenges surrounding the molecular recognition of RNA structures by small molecules. Here we developed a strategy that converts biologically inactive RNA-binding small molecules into potent and specific effectors of function, achieved by affixing an RNA molecular recognition element to a second compound that binds to and activates a ribonuclease to cleave the target.
"Programming inactive RNA-binding small molecules into bioactive degraders". Nature 2023
"Programming inactive RNA-binding small molecules into bioactive degraders". Nature 2023
We welcome Arijit, a new PhD student to the Benhamou lab!
Arijit joined us from India to pursue his PhD with us! Welcome and good luck Arijit!
New Grant! Science Forefront
The minister of science granted our research in collaboration with Dr. Gali Umshweif. We seek to develop novel molecules to fight depression.
We finally moved to our new lab space!
We have brand-new equipment and a splendid view over Jerusalem Mountain. If you are around come visit us!
New M.Sc. Students
We welcome Elias, Kisanet and Aseel! They are joining the lab as new M.Sc. students!
New Grant! Research Career Development Award, Israel Cancer Research Fund (ICRF).
Great news for the lab! We have been awarded the Research Career Development Award from ICRF, for the next 3 years. Thanks for your trust in our research!
New Funding! Personal Research Grant, Israel Science Foundation (ISF).
The Benhamou lab is awarded the Personal Research Grant from the Israel Science Foundation (ISF) for the next 4 years! (2022-2026)
New Funding! New-Faculty Equipment Grant, Israel Science Foundation (ISF).
The Benhamou lab is awarded the New-Faculty Equipment Grant from the Israel Science Foundation (ISF).
Congratulations to Dr. Raphael I. Benhamou for Winning the 2022 Alon Fellowship.
Congratulations to Dr. Raphael I. Benhamou from Institute for Drug Research ,School of Pharmacy on receiving the 2022 Alon Faculty Fellowship of Israel’s Council for Higher Education (CHE).
New publication- PNAS 2022
Drug discovery generally investigates one target at a time, in sharp contrast to living organisms, which mold ligands and targets by evolution of highly complex molecular interaction networks. We recapitulate this modality of discovery by encoding drug structures in DNA, allowing the entire DNA-encoded library to interact with thousands of RNA fold targets, and then decoding both drug and target by sequencing. This information serves as a filter to identify human RNAs aberrantly produced in cancer that are also binding partners of the discovered ligand, leading to a precision medicine candidate that selectively ablates an oncogenic noncoding RNA, reversing a disease-associated phenotype in cells.
Nano Center Annual Conference, 2022.
Every year, a two-day conference is held by the Center for Nanoscience and Nanotechnology. The event provides an excellent opportunity to present the research of the Center's members and their students and enhances the mutual interactions, connections and discussions.
NANOMED BIOCONVERGENCE, 21 FEB 2022. School of computer science and engineering.
The field of BioConvergence, combines biology and engineering and is expected to develop at the national level
bottom of page